SUMMARY -Lymphomas are very radiosensitive and radiotherapy (RT) was the fi rst treatment modality that enabled cure. It is the most eff ective single modality for local control of lymphomas. However, as a local form of treatment, curative intention is only possible if all lymphoma tissue can be incorporated in the volume to be irradiated with the prescribed total irradiation dose. Th at is why RT is a single modality only in early stage of nodular lymphocyte predominance Hodgkin's lymphoma and low grade non-Hodgkin's lymphoma. In most patients, RT can be used as consolidation therapy after chemotherapy or as salvage after failure of chemotherapy. In the past two decades, irradiation techniques have been improved in order to spare critical tissues and reduce toxicity. Although eff ective, RT is a neglected modality of treatment because of the appearance of new drugs and fear of side effects after irradiation. Radiation has been shown to be eff ective in the treatment of all stages and forms of lymphoma. Study data are still mostly derived from patients that received supradiaphragmal RT; therefore, there is no agreement about the best management approach in patients with infradiaphragmal lymphoma.
Introduction
Lymphomas are very radiosensitive and radiotherapy (RT) was the fi rst treatment modality that enabled cure. It is the most eff ective single modality for local control of lymphomas and an important part of the treatment for many patients. However, as a local form of treatment, curative intention is only possible if all lymphoma tissue can be incorporated into the volume that is irradiated with the total irradiation dose prescribed. Today, RT as a single modality is used as the primary treatment in early stage of nodular lymphocyte predominance of Hodgkin's lymphoma and in early stage of indolent non-Hodgkin's lymphoma (NHL). In most patients, RT is part of combined treatment modalities as consolidation after chemotherapy. In patients with advanced stages of the disease, RT can be used as part of the planned treatment when RT is applied to high-risk recurrence sites and in cases of insuffi cient response to chemotherapy [1] [2] [3] [4] [5] . Radiation has been shown to be eff ective in the treatment of all stages and forms of lymphoma, but there is no consensus on the size of the fi eld or the dose administered in the abdominal area. All current knowledge, radiation guidelines, and radiation side eff ects are retrieved for supradiaphragmal fi elds. Treatment of lymphoma in the abdominal area is the issue of existing controversy. Although eff ective, RT is a neglected form of treatment due to the appearance of new drugs and because of the fear of side eff ects after irradiation. In addition, there is no consensus about the use of RT as consolidation therapy after remission on chemotherapy or salvage RT when chemotherapy is unsuccessful.
Radiotherapy in the Treatment of Lymphomas
Since the discovery of x-rays, RT has played an important role in the treatment of lymphomas. At the beginning, RT was limited to temporary control and palliation. In the 1960s, RT was an almost exclusive modality in off ering a curative approach to early stage aggressive lymphomas 6, 7 . In stage I of the disease, treatment modality that included Involved Field (IFRT) or Extended Field (EFRT) radiotherapy provided approximately 50% cure rate. In stage II NHL, RT alone could not achieve cure. In stage II patients, survival was only 20%. Due to the systemic nature of many types of NHL and the introduction of highly eff ective chemotherapy protocols, RT was neglected as a treatment option in NHL patients. In the 1990s, RT had a great return in the treatment of both aggressive and indolent NHL 8, 9 . Most relapses in patients treated only with RT were either extra nodal or out-of-fi eld. Th e advent of eff ective chemotherapy protocols for aggressive NHL has led to practical abandoning RT from the treatment of patients in early NHL stages. Several randomized studies showed that adjuvant chemotherapy followed by radiation resulted in signifi cantly better survival without relapse than just RT in early stages. In some studies, better survival without relapse resulted in better overall survival [10] [11] [12] [13] [14] . Adjuvant RT has become the standard of treatment in early stages of aggressive NHL. Th is analysis is based on the two large randomized studies conducted by the Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG). Th ey demonstrated the superiority of the combined modality treatment versus chemotherapy alone in stage I and II high-grade lymphoma. Both studies confi rmed the importance of adjuvant RT for primary involvement of the disease in patients that achieved complete remission after a short (3-cycle) or long (8-cycle) chemotherapy protocol. Relatively low radiation doses of 30 Gy were suffi cient for patients with complete remission in the ECOG study. Higher radiation doses (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) were applied in the SWOG study 15, 16 . Poor results achieved by radiation alone and the occurrence of relapse outside the radiation fi eld in early stage NHL have demonstrated the systemic nature of aggressive lymphoma and stressed the importance of using chemotherapy in these situations. On the other hand, ECOG and SWOG studies emphasize that local therapy is an important component in the treatment, even in achieving complete remission in diseases that are primarily systemic 15, 16 . Th e role of RT in advanced stage aggressive NHL is still controversial. Some centers rarely recommend the use of adjuvant radiotherapy in patients with stage III and IV NHL, even in cases of bulky disease or partial response to chemotherapy.
Th e standard treatment of patients in advanced stages of (III and IV) of aggressive NHL is a combination of chemotherapy. Th e most eff ective and commonly used is the R-CHOP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen 17 . Th e use of RT as consolidation therapy in bulky disease or in patients with incomplete response was confi rmed in retrospective studies 18 . Some randomized studies indicated that RT, if applied to the areas primarily aff ected by bulky disease, could significantly contribute to relapse-free survival and overall survival in patients with complete remission upon chemotherapeutic treatment [19] [20] [21] [22] [23] . A study conducted in Mexico included 218 patients with stage IV diff use large B-cell lymphoma (DLBCL). Of these, 155 (71%) patients achieved complete remission on chemotherapy. Of the 155 patients that achieved complete remission, 88 (56%) patients presented bulky disease (>10 cm). Th ey were classifi ed into the group being observed or in the involved-fi eld RT (IFRT) group receiving 40-50 Gy. After 5 years, 43 (72%) patients that received RT compared to 45 (35%) patients in the non-irradiated group were alive and without signs of illness. Most relapses occurred in the primary area of the disease. Total survival was also better in the group of irradiated patients (81% vs. 55%; p<0.01) 11 . In a more recent study, 341 patients with aggressive DLBCL and nodal bulky (>10 cm) disease with pathologically proven complete remission after chemotherapy were randomized to the irradiated group (IFRT, 40 Gy) or to the group being monitored. Th e 5-year event-free survival and overall survival were signifi cantly better in the group of exposed patients (event-free survival 82% vs. 55%; p<0.001; overall survival 87% vs. 66%; p<0.01). RT was well tolerated and acute toxicity moderate 19 . In a Milan study, 97 patients with stage III to IV DLBCL that were in complete remission after che-motherapy were either observed or received consolidation RT. At 5 years, patients with bulky disease (<10 cm) that received RT had a signifi cantly longer time to relapse and better overall survival (p<0.05) compared with patients that were not irradiated. A multivariate analysis showed that the use of RT was an independent favorable prognostic factor for relapse (p<0.001) and survival (p<0.05) 12 . Non-Hodgkin's lymphoma is a systemic disease and all stages should be treated primarily with chemotherapy. RT to bulky or residual disease may improve the outcome of treatment. Th e potential benefi t of RT in advanced-stage disease is not approved in prospective randomized studies but the above data provide an adequate basis to justify the combined-modality approach in selected cases.
Radiation in the Abdominal Region
Since the introduction of RT in the treatment, in the 1950s and during the 1960s, the treatment of abdominal presentation of the lymphoma was performed by irradiation of the entire abdomen. Patient tolerance to such treatment was poor. Patients had a signifi cantly decreased blood cell count, diarrhea, nausea, feeling of increased tiredness, and loss of appetite 24 . According to Surbone et al., 30% of patients had an abdominal mass at diagnosis and 40% were left with a radiographically detectable residual mass at clinical complete remission. Th e likelihood of a residual mass was much higher in patients with bulky disease 23 . Results of several studies suggest that adding RT after chemotherapy treatment reduces the risk of local recurrence and improves survival without relapse [11] [12] [13] [18] [19] [20] 24 . Radiation is most eff ective in patients with poor prognostic factors (large tumor mass, extensive nodal involvement, and advanced stage of disease) and need adjuvant treatment to consolidate disease remission. It is possible to apply a more intensive chemotherapy scheme and bone marrow transplantation to achieve long lasting complete remission 27 . Although controversial, radiation in the abdominal area may be less toxic. Radiation can also be applied in refractory cases 28, 29 . Many studies confi rm the viability and effectiveness of salvage radiation of tumor mass in the abdominal area [30] [31] [32] [33] [34] . Th e fi rst article describing abdominal irradiation of NHL patients appeared in 1976. Inverted Y fi eld resulted in 29% of relapses. It was considered that the cause of such a high rate of local recurrence was the lack of coverage of mesenteric lymph nodes in the inverted Y fi eld of irradiation 31 . Later, Brihi et al. demonstrated that abdominal radiation was viable and eff ective in patients at a high risk of intra-abdominal relapse, for the treatment of residual disease after chemotherapy, and as palliative care that contributed to survival 29 .
Volume Defi nition and Side Eff ects of Infradiaphragmal Irradiation in Lymphoma Patients
Radiation techniques for lymphomas have significantly changed over the last few decades. Partially, this is due to the reduction of the fi eld boundaries and because of the introduction of combined treatment modalities and new drugs, which have superseded irradiation therapy as monotherapy.
Nowadays, large radiation fi elds that used to be applied are considered inadequate. Many of the historic concepts of dose and volume have been changed over the past few decades 22, 32, 33 . Irradiation therapy based on involved fi elds defi ned by anatomic landmarks and encompassing adjacent uninvolved lymph nodes is no longer appropriate for modern RT delivery.
Previously applied extended-fi eld (EFRT) and involved-fi eld (IFRT) RT techniques have been replaced with smaller volumes based solely on detectable nodal enrolment at presentation (involved site-ISRT/involved node-INRT) 20, [34] [35] [36] [37] [38] . Th is is due to the general progress in radiation imaging and computer technology, including the introduction of three-dimensional conformal RT (3D-CRT), intensity-modulated RT (IMRT), image-guided RT (IGRT) and 4-dimensional RT (4D-RT). Advanced RT techniques allow the achievement of steep dose gradients in the radiation fi eld along with spearing normal tissue. Initial diagnostic imaging (computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET)) facilitates the target volume defi nition, and signifi cant radiation dose reductions at the organs at risk (kidneys, spinal cord, esophagus, liver and intestine). Reduction of the radiation fi elds has reduced toxicity while maintaining a high cure rate in combined modality treatment. Th e aim is to reduce normal tissue exposure, but not to compromise eff ective local control with such a reduced fi eld size.
Volumes are delineated according to the International Commission on Radiation Units Measurement (ICRU) and ICRU supplements [39] [40] [41] , based on defi ning gross tumor volume (GTV) and clinical target volume (CTV). CTV has to be expanded to create planning target volume (PTV), which is used to defi ne dose coverage. Implementation of other imaging methods such as PET/CT has enabled more precise target borders and volume determination. Th anks to CT planning and the possibilities to design the radiation plan in three dimensions, it is possible to defi ne the volumes and doses to each volume of irradiation much more precisely. Th ey allow the defi nition of planning volumes around the lymph node that have been aff ected, thus reducing the risk of toxicity and late side eff ects.
Pre-chemotherapy or preoperative GTV makes all areas aff ected by the disease before any intervention and should be labeled on the simulation CT because these volumes should be included in the CTV. CTV covers the original GTV (before any intervention), even if it extends beyond the original tissue and organs. Normal structures such as kidneys and muscles, which obviously were not aff ected, although displaced by GTV, should be excluded from CTV, depending on clinical judgment. PTV should be created by adding margin taking into account uncertainties in positioning the patients and adjusting the photons during irradiation delivery. Th is is the volume that has to be irradiated to make the CTV irradiated with the prescribed dose. PTV diff ers from institution to institution and needs to be calculated and determined in each case individually 32, 33 .
Organs at Risk
Th e organs at risk (OAR) are critical organs or healthy organs near the irradiation fi eld and they can cause signifi cant morbidity if irradiated. Th is aff ects the treatment planning or determination of the radiation dose. Current knowledge of radiation toxicity is derived from conventional and newer 3D-CRT data. Th e Quantitative Analyses of Normal Tissue Eff ects in the Clinic (QUANTEC) project has produced data that are currently used to predict RT side eff ects and the plausibility of evaluated treatment plans 42 . Before being approved, all RT treatment plans have to be evaluated for the probability of organ-specifi c radiation toxicity. Th e clinician should consider dose-volume histograms and determine the likelihood of complications of healthy tissue, and then approve the radiation plan. Th e number of organs at risk and the volume of normal tissue found in the radiation fi eld may be signifi cant. Due attention should be paid to short-term side eff ects and long-term morbidity, and accordingly target volume should be planned. Infradiaphragmal organs that limit the dose of radiation are spinal cord, kidneys, liver, and gastrointestinal system. Fortunately, doses that are used in lymphoma treatment are usually below the toxicity threshold for most organs. However, due to long survival rate and follow up of the patients, even small doses cannot be ignored.
Th ere are dose limits for the organs at risk that have to be estimated but these doses are easy to meet within the lymphoma RT plans as radiation doses are signifi cantly lower than in other solid tumors. However, dose limits and their compliance do not guarantee optimization of the plan in terms of side eff ects and complications of treatment. Long survival rate after combined modality treatment poses the risk of secondary malignancies or morbidities occurring in the radiation fi eld.
Liver
Th e mean dose to the liver should be ≤30 Gy because in 5% of patients it may cause radiation-induced liver disease (anicteric hepatomegaly, ascites, increased alkaline phospahtase). It typically occurs between 2 weeks and 3 months after RT 43 .
Kidneys
Kidneys are parallel organs, which means that one kidney can take over the role of the other one. So, radiation-induced renal dysfunction can be expressed in various ways, including decrease in creatinine clearance, biochemical changes and radiologic fi ndings to renal failure. QUANTEC has estimated a <5% risk of injury in 5 years when the mean kidney dose is limited to <18 Gy 44 .
Stomach and small bowel
Nausea and vomiting are radiation-induced acute toxicity. Th ey can occur within hours after RT to stom-ach or small-bowel. RT-induced injury to the stomach can range from self-limited mucosal infl ammation causing dyspepsia to ulceration and bleeding. RT-induced small bowel mucositis can be expressed as cramping and diarrhea.
Late radiation-induced toxicity to the stomach includes dyspepsia and ulceration. A whole organ dose of 50 Gy has been associated with 2% to 6% risk of severe late toxicity.
Th e volume of the small bowel receiving relatively low doses of radiation plays a signifi cant role in the rate of acute toxicity. When contouring individual bowel loops, the rate of grade ≥3 acute toxicity is <10% when V15 <120 cc. When the entire potential space within the peritoneal cavity is contoured, a V45<195 cc results in <10% acute toxicity 45 .
Pancreas
Radiation to para-aortic lymph nodes increases the risk of developing diabetes mellitus in 5-year Hodgkin's lymphoma survivors. Radiation dose ≥36 Gy is associated with 2-fold increased risk of diabetes mellitus 46 .
Spinal cord
With conventional fractionation of 2 Gy per day including the full cord cross-section, a total RT dose of 50, 60 and 70 Gy is associated with 0.2%, 6% and 50% rate of myelopathy, respectively. Re-irradiation data in animals and humans suggest partial repair of RT-induced subclinical damage becoming evident about 6 months post-RT and increasing over the next 2 years 47 . Total dose to spinal cord in Hodgkin's lymphoma and NHL patients is usually around 30 Gy, so myelopathy is not an issue.
Conclusion
Radiotherapy is an eff ective and safe treatment option for patients with localized abdominal lymphoma. Modern RT for lymphomas is a highly individualized treatment. Th e newly defi ned concept of involved site RT that uses modern imaging and RT techniques should be incorporated in everyday practice to minimize the risk of long-term complications while achieving high local control and long-term survival. Th e optimal outcome for patients with lymphoma is only possible with collaborative multidisciplinary approach.
